Ildong Pharmaceutical Co., Ltd. (249420.KS)
KRW 11350.0
(-5.42%)
KRW 11350.0
(-5.42%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 164.58 Billion KRW | 5.77% |
| 2022 | 155.6 Billion KRW | 71.8% |
| 2021 | 90.56 Billion KRW | 11.41% |
| 2020 | 81.29 Billion KRW | 7.02% |
| 2019 | 75.96 Billion KRW | 39.48% |
| 2018 | 54.46 Billion KRW | -39.79% |
| 2017 | 90.45 Billion KRW | -18.14% |
| 2016 | 110.49 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 170.69 Billion KRW | 3.71% |
| 2024 Q2 | 178.01 Billion KRW | 4.29% |
| 2023 Q4 | 164.58 Billion KRW | 4302.11% |
| 2023 FY | 164.58 Billion KRW | 5.77% |
| 2023 Q2 | 183.49 Billion KRW | 12.58% |
| 2023 Q1 | 162.99 Billion KRW | 4.75% |
| 2023 Q3 | 3.73 Billion KRW | -97.96% |
| 2022 Q1 | 85.9 Billion KRW | -5.15% |
| 2022 Q4 | 155.6 Billion KRW | 19.57% |
| 2022 Q3 | 130.13 Billion KRW | 17.2% |
| 2022 Q2 | 111.03 Billion KRW | 29.26% |
| 2022 FY | 155.6 Billion KRW | 71.8% |
| 2021 Q2 | 70.76 Billion KRW | -13.35% |
| 2021 Q3 | 81.2 Billion KRW | 14.75% |
| 2021 Q4 | 90.56 Billion KRW | 11.53% |
| 2021 FY | 90.56 Billion KRW | 11.41% |
| 2021 Q1 | 81.66 Billion KRW | 0.46% |
| 2020 Q1 | 79.98 Billion KRW | 5.29% |
| 2020 Q2 | 86.13 Billion KRW | 7.69% |
| 2020 FY | 81.29 Billion KRW | 7.02% |
| 2020 Q4 | 81.29 Billion KRW | -1.76% |
| 2020 Q3 | 82.74 Billion KRW | -3.94% |
| 2019 Q4 | 75.96 Billion KRW | 1.01% |
| 2019 Q3 | 75.2 Billion KRW | 4.92% |
| 2019 Q2 | 71.67 Billion KRW | 0.72% |
| 2019 Q1 | 71.16 Billion KRW | 30.67% |
| 2019 FY | 75.96 Billion KRW | 39.48% |
| 2018 Q2 | 83.63 Billion KRW | -1.17% |
| 2018 Q4 | 54.46 Billion KRW | -28.26% |
| 2018 Q1 | 84.62 Billion KRW | -6.45% |
| 2018 Q3 | 75.91 Billion KRW | -9.23% |
| 2018 FY | 54.46 Billion KRW | -39.79% |
| 2017 Q3 | 81.95 Billion KRW | -13.22% |
| 2017 Q1 | 96.44 Billion KRW | -12.71% |
| 2017 FY | 90.45 Billion KRW | -18.14% |
| 2017 Q2 | 94.43 Billion KRW | -2.08% |
| 2017 Q4 | 90.45 Billion KRW | 10.38% |
| 2016 FY | 110.49 Billion KRW | 0.0% |
| 2016 Q4 | 110.49 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1769.778% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 71.228% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 47.058% |
| HANDOK Inc. | 283.45 Billion KRW | 41.937% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -719.954% |
| Yuhan Corporation | -69.18 Billion KRW | 337.883% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 15.142% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 4565.298% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 68.22% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 607.471% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -117.487% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -346.782% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -99.445% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -555.488% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1769.778% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 202.962% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 18.096% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 3.721% |
| JW Holdings Corporation | 480.68 Billion KRW | 65.761% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -139932.842% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -6.615% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -6899.588% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -615.532% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 5.938% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -216.66% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1769.778% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | -3.971% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 54.05% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -6.615% |
| Yuhan Corporation | -69.18 Billion KRW | 337.883% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | -21.024% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -175.802% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 61.649% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -6.615% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | -41.593% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -902.019% |
| CKD Bio Corp. | 143.29 Billion KRW | -14.855% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -41.8% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 784.002% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 467.913% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -6899.588% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 61.077% |
| Boryung Corporation | 187.72 Billion KRW | 12.329% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 329.096% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -117.487% |
| JW Lifescience Corporation | 26.09 Billion KRW | -530.81% |